JC13 P PCT/PTO 28 MAR 2002

					امال	31 170	11/Piu 2	8 MAR 2002
FORM PTO-1449 U.S. Department of Commo Patent and Trademark Office					Attorney Docket Number 9099-21P		Application No.	
LIST	LIST OF DOCUMENTS CITED BY APPLICANT							To Be Assigned
	(Us	e several sheets if	necessary)					
			•		Applicants:	Scarantino e	t al.	1
					Filing Date	Concurrently	Herewith	Group
			U. S	PATENT DO	CUMENTS	<b>,</b>		••
Examiner Initial		Document Number	Date	N	ame	Class	Subclass	Filing Date if Appropriate
BN	1	4,655,880	04/07/87	Liu		204	1 T	
	2	4,571,292	02/18/86	Liu et al.		204	412	
	3	Re. 32,361	02/24/87	Duggan		128	696	Re. 32,361
	4	3,638,640	02/01/72	Shaw		128	2R	3,638,640
	45	3,972,320	08/03/76	Kalman		128	002.1A	3,972,320
	6	4,163,380	08/07/79	Masoner		72	342	4,163,380
	7	4,326,535	04/27/82	Steffel et al.		128	631	4,326,535
	8	4,361,153	11/30/82	Slocum et al.		128	419.P	4,361,153
	9	4,397,313	08/09/83	Vaguine		128	399	4,397,313
	10	4,397,314	08/09/83	Vaguine		128	399	4,397,314
	11	4,416,283	11/22/83	Slocum		128	419 PG	4,416,283
	12	4,431,004	02/14/84	Bessman et a	1.	128	635	4,431,004
	13	4,494,545	01/22/85	Slocum et al.		128	1.5	4,494,545
	14	4,519,401	05/28/85	Ko et al.		118	748	4,519,401
	15	4,523,279	06/11/85	Sperinde et a	1.	364	416	4,523,279
	16	4,541,901	09/17/85	Parker et al.		29\04	1 T	4,541,901
	17	4,543,953	10/01/85	Slocum et al.		128	419.PT	4,543,953
	18	4,556,063	12/03/85	Thompson et	al.	128	419.PT	4,556,063
	19	4,571,292	02/18/86	Liu et al.		204	412	4,571,292
	20	4,571,589	02/18/86	Slocum et al.		128	419 PG	4,571,589
	21	4,575,676	03/11/86	Palkuti		324	158 D	4,575,676
	22	4,625,733	12/02/86	Säynäjäkanga	as	128	687	4,625,733
	23	4,638,436	01/20/87	Badger et al.		364	414	4,638,436
	24	4,651,741	03/24/87	Passafaro		128	633	4,651,741
V	25	4,655,880	04/07/87	Liu		204	1 T	4,655,880
BN	26	4,681,111	07/21/87	Silvian		128	419.PT	4,681,111

162556751.23 28 Sheet 2 of 8

No. To Be								فيدن ً تا والق كا ف	20 MAR 2002
Assigned   Assigned   Assigned   Assigned   Assigned   Assigned   Applicants: Searantino et al.   Filing Date   Concurrently Herewith   Group	FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office					Attorney Doc	ket Number	9099-2IP	No.
Applicants: Scarantino et al.   Filing Date   Concurrently Herewith   Group	LIS								
Filing Date   Concurrently   Herewith   Group		(Us	e several sheets if	necessary)					
BN 27 4,703,756 11/03/87 Gough et al. 128 635 4,703,756  28 4,719,919 01/19/88 Marchosky et al. 128 401 4,719,919  29 4,750,495 06/14/88 Moore et al. 128 419 PG 4,750,495  30 4,769,547 09/06/88 Uber III 250 374 4,769,547  31 4,793,825 12/27/88 Benjamin et al. 128 419 4,793,825  32 4,796,641 01/10/89 Mills et al. 128 419 4,793,825  33 4,804,847 02/14/89 Uber III 250 370 F  34 4,846,191 07/11/89 Brockway et al. 128 748  35 4,847,617 07/11/89 Brockway et al. 128 748  36 4,900,422 02/13/90 Bryan et al. 204 401  37 4,919,141 04/24/90 Zier et al. 128 635  38 4,935,345 06/19/90 Guilbeau et al. 435 014  39 4,944,299 07/31/90 Silvian 128 419.PG  40 4,958,645 09/25/90 Cadell et al. 128 399  41 4,961,422 10/09/90 Marchosky et al. 128 399  42 4,970,391 11/13/90 Uber , III 250 374  43 4,976,266 12/11/90 Huffman et al. 128 659  44 4,989,601 02/05/19 Marchosky et al. 128 399  45 5,008,546 04/16/91 Marchosky et al. 128 399  45 5,008,546 04/16/91 Marchosky et al. 128 399  45 5,008,546 04/16/91 Marchosky et al. 128 399  45 5,008,547 03/24/92 Bryan et al. 128 399  45 5,008,546 04/16/91 Marchosky et al. 128 399  45 5,008,547 03/24/92 Bryan et al. 128 399  46 5,117,824 06/02/92 Keimel et al. 128 419 PG  50 5,126,937 06/30/92 Yamaguchi et al. 128 419 PG  51 5,127,404 07/07/92 Wyborny et al. 128 419 PT  52 5,137,022 08/11/92 Henry 128 419.PT  53 5,163,380 11/17/92 Duffy et al. 119 015						Applicants:	Scarantino e	t al.	
28 4,719,919 01/19/88 Marchosky et al. 128 401 4,719,919 29 4,750,495 06/14/88 Moore et al. 128 419 PG 4,750,495 30 4,769,547 09/06/88 Uber III 250 374 4,769,547 31 4,793,825 12/27/88 Benjamin et al. 128 419 4,793,825 32 4,796,641 01/10/89 Mills et al. 128 748 4,796,641 33 4,804,847 02/14/89 Uber III 250 370 F 34 4,846,191 07/11/89 Brockway et al. 128 748 35 4,847,617 07/11/89 Silvian 340 970,160 36 4,900,422 02/13/90 Bryan et al. 204 401 37 4,919,141 04/24/90 Zier et al. 128 635 38 4,935,345 06/19/90 Guilbeau et al. 435 014 39 4,944,299 07/31/90 Silvian 128 419.PG 40 4,958,645 09/25/90 Cadell et al. 128 399 41 4,961,422 10/09/90 Marchosky et al. 128 399 42 4,970,391 11/13/90 Uber , III 250 374 43 4,976,266 12/11/90 Huffman et al. 128 659 44 4,989,601 02/05/91 Marchosky et al. 128 399 45 5,008,546 04/16/91 Mazziotta et al. 250 366 46 5,012,411 04/30/91 Policastro et al. 264 401 48 5,109,850 05/05/92 Blanco et al. 128 419.PG 50 5,126,937 06/30/92 Yamaguchi et al. 128 419.PG 51 5,127,404 07/07/92 Wyborny et al. 128 419.PG 52 5,137,022 08/11/92 Henry 128 419.PT 53 5,163,380 11/17/92 Duffy et al. 119 015						Filing Date	Concurrently	Herewith	Group
29 4,750,495	BN	27	4,703,756	11/03/87	Gough et al.		128	635	4,703,756
30 4,769,547 09/06/88 Uber III 250 374 4,769,547  31 4,793,825 12/27/88 Benjamin et al. 128 419 4,793,825  32 4,796,641 01/10/89 Mills et al. 128 748 4,796,641  33 4,804,847 02/14/89 Uber III 250 370 F  34 4,846,191 07/11/89 Brockway et al. 128 748  35 4,847,617 07/11/89 Silvian 340 970.160  36 4,900,422 02/13/90 Bryan et al. 204 401  37 4,919,141 04/24/90 Zier et al. 128 635  38 4,935,345 06/19/90 Guilbeau et al. 435 014  39 4,944,299 07/31/90 Silvian 128 419.PG  40 4,958,645 09/25/90 Cadell et al. 128 399  41 4,961,422 10/09/90 Marchosky et al. 128 399  42 4,970,391 11/13/90 Uber , III 250 374  43 4,976,266 12/11/90 Huffman et al. 128 659  44 4,989,601 02/05/91 Marchosky et al. 128 399  45 5,008,546 04/16/91 Mazziotta et al. 250 366  46 5,012,411 04/30/91 Policastro et al. 364 413.06  47 5,098,547 03/24/92 Bryan et al. 204 401  48 5,109,850 05/05/92 Blanco et al. 128 419.PG  50 5,126,937 06/30/92 Yamaguchi et al. 128 419.PG  51 5,127,404 07/07/92 Wyborny et al. 128 419.P  52 5,137,022 08/11/92 Henry 128 419.PT  53 5,163,380 11/17/92 Duffy et al. 119 015		28	4,719,919	01/19/88	Marchosky et	al.	128	401	4,719,919
31 4,793,825 12/27/88 Benjamin et al. 128 419 4,793,825  32 4,796,641 01/10/89 Mills et al. 128 748 4,796,641  33 4,804,847 02/14/89 Uber III 250 370 F  34 4,846,191 07/11/89 Brockway et al. 128 748  35 4,847,617 07/11/89 Silvian 340 970.160  36 4,900,422 02/13/90 Bryan et al. 204 401  37 4,919,141 04/24/90 Zier et al. 128 635  38 4,935,345 06/19/90 Guilbeau et al. 435 014  39 4,944,299 07/31/90 Silvian 128 419.PG  40 4,958,645 09/25/90 Cadell et al. 128 399  41 4,961,422 10/09/90 Marchosky et al. 128 399  42 4,970,391 11/13/90 Uber , III 250 374  43 4,976,266 12/11/90 Huffman et al. 128 659  44 4,989,601 02/05/91 Marchosky et al. 128 399  45 5,008,546 04/16/91 Mazziotta et al. 250 366  46 5,012,411 04/30/91 Policastro et al. 364 413.06  47 5,098,547 03/24/92 Bryan et al. 204 401  48 5,109,850 05/05/92 Blanco et al. 128 419.PG  50 5,126,937 06/30/92 Yamaguchi et al. 128 419.PG  51 5,127,404 07/07/92 Wyborny et al. 128 419.P  52 5,137,022 08/11/92 Henry 128 419.PT  53 5,163,380 11/17/92 Duffy et al. 119 015		29	4,750,495	06/14/88	Moore et al.		128	419 PG	4,750,495
32 4,796,641 01/10/89 Mills et al. 128 748 4,796,641  33 4,804,847 02/14/89 Uber III 250 370 F  34 4,846,191 07/11/89 Brockway et al. 128 748  35 4,847,617 07/11/89 Silvian 340 970.160  36 4,900,422 02/13/90 Bryan et al. 204 401  37 4,919,141 04/24/90 Zier et al. 128 635  38 4,935,345 06/19/90 Guilbeau et al. 435 014  39 4,944,299 07/31/90 Silvian 128 419.PG  40 4,958,645 09/25/90 Cadell et al. 128 399  41 4,961,422 10/09/90 Marchosky et al. 128 399  42 4,970,391 11/13/90 Uber , III 250 374  43 4,976,266 12/11/90 Huffman et al. 128 659  44 4,989,601 02/05/91 Marchosky et al. 128 399  45 5,008,546 04/16/91 Mazziotta et al. 250 366  46 5,012,411 04/30/91 Policastro et al. 364 413.06  47 5,098,547 03/24/92 Bryan et al. 204 401  48 5,109,850 05/05/92 Blanco et al. 128 635  49 5,117,824 06/02/92 Keimel et al. 128 419.PG  50 5,126,937 06/30/92 Yamaguchi et al. 364 413.11  51 5,127,404 07/07/92 Wyborny et al. 128 419.PF  53 5,163,380 11/17/92 Duffy et al. 119 015		30	4,769,547	09/06/88	Uber III		250	374	4,769,547
33 4,804,847 02/14/89 Uber III 250 370 F  34 4,846,191 07/11/89 Brockway et al. 128 748  35 4,847,617 07/11/89 Silvian 340 970.160  36 4,900,422 02/13/90 Bryan et al. 204 401  37 4,919,141 04/24/90 Zier et al. 128 635  38 4,935,345 06/19/90 Guilbeau et al. 435 014  39 4,944,299 07/31/90 Silvian 128 419.PG  40 4,958,645 09/25/90 Cadell et al. 128 903  41 4,961,422 10/09/90 Marchosky et al. 128 399  42 4,970,391 11/13/90 Uber , III 250 374  43 4,976,266 12/11/90 Huffman et al. 128 399  44 4,989,601 02/05/91 Marchosky et al. 128 399  45 5,008,546 04/16/91 Mazziotta et al. 250 366  46 5,012,411 04/30/91 Policastro et al. 364 413.06  47 5,098,547 03/24/92 Bryan et al. 204 401  48 5,109,850 05/05/92 Blanco et al. 128 635  49 5,117,824 06/02/92 Keimel et al. 128 419 PG  50 5,126,937 06/30/92 Yamaguchi et al. 364 413.11  51 5,127,404 07/07/92 Wyborny et al. 128 419.PG  52 5,137,022 08/11/92 Henry 128 419.PT  53 5,163,380 11/17/92 Duffy et al. 119 015  54 5,186,172 02/16/93 Fiddian-Green 128 632		31	4,793,825	12/27/88	Benjamin et a	al.	128	419	4,793,825
34 4,846,191 07/11/89 Brockway et al. 128 748  35 4,847,617 07/11/89 Silvian 340 970.160  36 4,900,422 02/13/90 Bryan et al. 204 401  37 4,919,141 04/24/90 Zier et al. 128 635  38 4,935,345 06/19/90 Guilbeau et al. 435 014  39 4,944,299 07/31/90 Silvian 128 419.PG  40 4,958,645 09/25/90 Cadell et al. 128 903  41 4,961,422 10/09/90 Marchosky et al. 128 399  42 4,970,391 11/13/90 Uber , III 250 374  43 4,976,266 12/11/90 Huffman et al. 128 659  44 4,989,601 02/05/91 Marchosky et al. 128 399  45 5,008,546 04/16/91 Mazziotta et al. 250 366  46 5,012,411 04/30/91 Policastro et al. 364 413.06  47 5,098,547 03/24/92 Bryan et al. 204 401  48 5,109,850 05/05/92 Blanco et al. 128 635  49 5,117,824 06/02/92 Keimel et al. 128 419.PG  50 5,126,937 06/30/92 Yamaguchi et al. 128 419.PF  51 5,127,404 07/07/92 Wyborny et al. 128 419.PT  53 5,163,380 11/17/92 Duffy et al. 119 015  54 5,186,172 02/16/93 Fiddian-Green 128 632		32	4,796,641	01/10/89	Mills et al.		128	748	4,796,641
35 4,847,617 07/11/89 Silvian 340 970.160  36 4,900,422 02/13/90 Bryan et al. 204 401  37 4,919,141 04/24/90 Zier et al. 128 635  38 4,935,345 06/19/90 Guilbeau et al. 435 014  39 4,944,299 07/31/90 Silvian 128 419.PG  40 4,958,645 09/25/90 Cadell et al. 128 399  41 4,961,422 10/09/90 Marchosky et al. 128 399  42 4,970,391 11/13/90 Uber , III 250 374  43 4,976,266 12/11/90 Huffman et al. 128 659  44 4,989,601 02/05/91 Marchosky et al. 128 399  45 5,008,546 04/16/91 Mazziotta et al. 250 366  46 5,012,411 04/30/91 Policastro et al. 364 413.06  47 5,098,547 03/24/92 Bryan et al. 204 401  48 5,109,850 05/05/92 Blanco et al. 128 419.PG  50 5,126,937 06/30/92 Keimel et al. 364 413.11  51 5,127,404 07/07/92 Wyborny et al. 128 419.PF  53 5,163,380 11/17/92 Duffy et al. 119 015  54 5,186,172 02/16/93 Fiddian-Green 128 632		33	4,804,847	02/14/89	Uber III		250	370 F	
36 4,900,422 02/13/90 Bryan et al. 204 401  37 4,919,141 04/24/90 Zier et al. 128 635  38 4,935,345 06/19/90 Guilbeau et al. 435 014  39 4,944,299 07/31/90 Silvian 128 419.PG  40 4,958,645 09/25/90 Cadell et al. 128 903  41 4,961,422 10/09/90 Marchosky et al. 128 399  42 4,970,391 11/13/90 Uber , III 250 374  43 4,976,266 12/11/90 Huffman et al. 128 659  44 4,989,601 02/05/91 Marchosky et al. 128 399  45 5,008,546 04/16/91 Mazziotta et al. 250 366  46 5,012,411 04/30/91 Policastro et al. 364 413.06  47 5,098,547 03/24/92 Bryan et al. 204 401  48 5,109,850 05/05/92 Blanco et al. 128 635  49 5,117,824 06/02/92 Keimel et al. 128 419 PG  50 5,126,937 06/30/92 Yamaguchi et al. 364 413.11  51 5,127,404 07/07/92 Wyborny et al. 128 419.PT  53 5,163,380 11/17/92 Duffy et al. 119 015		34	4,846,191	07/11/89	Brockway et	al.	128	748	
37 4,919,141 04/24/90 Zier et al. 128 635  38 4,935,345 06/19/90 Guilbeau et al. 435 014  39 4,944,299 07/31/90 Silvian 128 419.PG  40 4,958,645 09/25/90 Cadell et al. 128 903  41 4,961,422 10/09/90 Marchosky et al. 128 399  42 4,970,391 11/13/90 Uber , III 250 374  43 4,976,266 12/11/90 Huffman et al. 128 659  44 4,989,601 02/05/91 Marchosky et al. 128 399  45 5,008,546 04/16/91 Mazziotta et al. 250 366  46 5,012,411 04/30/91 Policastro et al. 364 413.06  47 5,098,547 03/24/92 Bryan et al. 204 401  48 5,109,850 05/05/92 Blanco et al. 128 635  49 5,117,824 06/02/92 Keimel et al. 128 419 PG  50 5,127,404 07/07/92 Wyborny et al. 128 419.PT  51 5,127,404 07/07/92 Wyborny et al. 128 419.PT  52 5,137,022 08/11/92 Henry 128 419.PT  53 5,163,380 11/17/92 Duffy et al. 119 015		35	4,847,617	07/11/89	Silvian		340	970.160	
38 4,935,345 06/19/90 Guilbeau et al. 435 014  39 4,944,299 07/31/90 Silvian 128 419.PG  40 4,958,645 09/25/90 Cadell et al. 128 903  41 4,961,422 10/09/90 Marchosky et al. 128 399  42 4,970,391 11/13/90 Uber , III 250 374  43 4,976,266 12/11/90 Huffman et al. 128 659  44 4,989,601 02/05/91 Marchosky et al. 128 399  45 5,008,546 04/16/91 Mazziotta et al. 250 366  46 5,012,411 04/30/91 Policastro et al. 364 413.06  47 5,098,547 03/24/92 Bryan et al. 204 401  48 5,109,850 05/05/92 Blanco et al. 128 635  49 5,117,824 06/02/92 Keimel et al. 128 419 PG  50 5,126,937 06/30/92 Yamaguchi et al. 364 413.11  51 5,127,404 07/07/92 Wyborny et al. 128 419.P  52 5,137,022 08/11/92 Henry 128 419.PT  53 5,163,380 11/17/92 Duffy et al. 119 015		36	4,900,422	02/13/90	Bryan et al.		204	401	
39 4,944,299 07/31/90 Silvian 128 419.PG 40 4,958,645 09/25/90 Cadell et al. 128 903 41 4,961,422 10/09/90 Marchosky et al. 128 399 42 4,970,391 11/13/90 Uber , III 250 374 43 4,976,266 12/11/90 Huffman et al. 128 659 44 4,989,601 02/05/91 Marchosky et al. 128 399 45 5,008,546 04/16/91 Mazziotta et al. 250 366 46 5,012,411 04/30/91 Policastro et al. 364 413.06 47 5,098,547 03/24/92 Bryan et al. 204 401 48 5,109,850 05/05/92 Blanco et al. 128 635 49 5,117,824 06/02/92 Keimel et al. 128 419 PG 50 5,126,937 06/30/92 Yamaguchi et al. 364 413.11 51 5,127,404 07/07/92 Wyborny et al. 128 419.P 52 5,137,022 08/11/92 Henry 128 419.PT 53 5,163,380 11/17/92 Duffy et al. 119 015 54 5,186,172 02/16/93 Fiddian-Green 128 632		37	4,919,141	04/24/90	Zier et al.		128	635	
40 4,958,645 09/25/90 Cadell et al. 128 903  41 4,961,422 10/09/90 Marchosky et al. 128 399  42 4,970,391 11/13/90 Uber , III 250 374  43 4,976,266 12/11/90 Huffman et al. 128 659  44 4,989,601 02/05/91 Marchosky et al. 128 399  45 5,008,546 04/16/91 Mazziotta et al. 250 366  46 5,012,411 04/30/91 Policastro et al. 364 413.06  47 5,098,547 03/24/92 Bryan et al. 204 401  48 5,109,850 05/05/92 Blanco et al. 128 635  49 5,117,824 06/02/92 Keimel et al. 128 419 PG  50 5,126,937 06/30/92 Yamaguchi et al. 364 413.11  51 5,127,404 07/07/92 Wyborny et al. 128 419.P  52 5,137,022 08/11/92 Henry 128 419.PT  53 5,163,380 11/17/92 Duffy et al. 119 015		38	4,935,345	06/19/90	Guilbeau et a	1.	435	014	
41 4,961,422 10/09/90 Marchosky et al. 128 399  42 4,970,391 11/13/90 Uber , III 250 374  43 4,976,266 12/11/90 Huffman et al. 128 659  44 4,989,601 02/05/91 Marchosky et al. 128 399  45 5,008,546 04/16/91 Mazziotta et al. 250 366  46 5,012,411 04/30/91 Policastro et al. 364 413.06  47 5,098,547 03/24/92 Bryan et al. 204 401  48 5,109,850 05/05/92 Blanco et al. 128 635  49 5,117,824 06/02/92 Keimel et al. 128 419 PG  50 5,126,937 06/30/92 Yamaguchi et al. 364 413.11  51 5,127,404 07/07/92 Wyborny et al. 128 419.P  52 5,137,022 08/11/92 Henry 128 419.PT  53 5,163,380 11/17/92 Duffy et al. 119 015		39	4,944,299	07/31/90	Silvian		128	419.PG	
42       4,970,391       11/13/90       Uber , III       250       374         43       4,976,266       12/11/90       Huffman et al.       128       659         44       4,989,601       02/05/91       Marchosky et al.       128       399         45       5,008,546       04/16/91       Mazziotta et al.       250       366         46       5,012,411       04/30/91       Policastro et al.       364       413.06         47       5,098,547       03/24/92       Bryan et al.       204       401         48       5,109,850       05/05/92       Blanco et al.       128       635         49       5,117,824       06/02/92       Keimel et al.       128       419 PG         50       5,126,937       06/30/92       Yamaguchi et al.       364       413.11         51       5,127,404       07/07/92       Wyborny et al.       128       419.PT         53       5,163,380       11/17/92       Duffy et al.       119       015         54       5,186,172       02/16/93       Fiddian-Green       128       632		40	4,958,645	09/25/90	Cadell et al.		128	903	
43 4,976,266 12/11/90 Huffman et al. 128 659  44 4,989,601 02/05/91 Marchosky et al. 128 399  45 5,008,546 04/16/91 Mazziotta et al. 250 366  46 5,012,411 04/30/91 Policastro et al. 364 413.06  47 5,098,547 03/24/92 Bryan et al. 204 401  48 5,109,850 05/05/92 Blanco et al. 128 635  49 5,117,824 06/02/92 Keimel et al. 128 419 PG  50 5,126,937 06/30/92 Yamaguchi et al. 364 413.11  51 5,127,404 07/07/92 Wyborny et al. 128 419.P  52 5,137,022 08/11/92 Henry 128 419.PT  53 5,163,380 11/17/92 Duffy et al. 119 015		41	4,961,422	10/09/90	Marchosky e	t al.	128	399	
44       4,989,601       02/05/91       Marchosky et al.       128       399         45       5,008,546       04/16/91       Mazziotta et al.       250       366         46       5,012,411       04/30/91       Policastro et al.       364       413.06         47       5,098,547       03/24/92       Bryan et al.       204       401         48       5,109,850       05/05/92       Blanco et al.       128       635         49       5,117,824       06/02/92       Keimel et al.       128       419 PG         50       5,126,937       06/30/92       Yamaguchi et al.       364       413.11         51       5,127,404       07/07/92       Wyborny et al.       128       419.P         52       5,137,022       08/11/92       Henry       128       419.PT         53       5,163,380       11/17/92       Duffy et al.       119       015         54       5,186,172       02/16/93       Fiddian-Green       128       632		42	4,970,391	11/13/90	Uber , III	•	250	374	
44 4,989,601 02/05/91 Marchosky et al. 128 399  45 5,008,546 04/16/91 Mazziotta et al. 250 366  46 5,012,411 04/30/91 Policastro et al. 364 413.06  47 5,098,547 03/24/92 Bryan et al. 204 401  48 5,109,850 05/05/92 Blanco et al. 128 635  49 5,117,824 06/02/92 Keimel et al. 128 419 PG  50 5,126,937 06/30/92 Yamaguchi et al. 364 413.11  51 5,127,404 07/07/92 Wyborny et al. 128 419.P  52 5,137,022 08/11/92 Henry 128 419.PT  53 5,163,380 11/17/92 Duffy et al. 119 015		43	4,976,266	12/11/90	Huffman et a	1.	128	659	
46       5,012,411       04/30/91       Policastro et al.       364       413.06         47       5,098,547       03/24/92       Bryan et al.       204       401         48       5,109,850       05/05/92       Blanco et al.       128       635         49       5,117,824       06/02/92       Keimel et al.       128       419 PG         50       5,126,937       06/30/92       Yamaguchi et al.       364       413.11         51       5,127,404       07/07/92       Wyborny et al.       128       419.P         52       5,137,022       08/11/92       Henry       128       419.PT         53       5,163,380       11/17/92       Duffy et al.       119       015         54       5,186,172       02/16/93       Fiddian-Green       128       632		44	4,989,601	02/05/91	Marchosky e	t al.	128	399	
47       5,098,547       03/24/92       Bryan et al.       204       401         48       5,109,850       05/05/92       Blanco et al.       128       635         49       5,117,824       06/02/92       Keimel et al.       128       419 PG         50       5,126,937       06/30/92       Yamaguchi et al.       364       413.11         51       5,127,404       07/07/92       Wyborny et al.       128       419.P         52       5,137,022       08/11/92       Henry       128       419.PT         53       5,163,380       11/17/92       Duffy et al.       119       015         54       5,186,172       02/16/93       Fiddian-Green       128       632		45	5,008,546	04/16/91	Mazziotta et	al.	250	366	
48       5,109,850       05/05/92       Blanco et al.       128       635         49       5,117,824       06/02/92       Keimel et al.       128       419 PG         50       5,126,937       06/30/92       Yamaguchi et al.       364       413.11         51       5,127,404       07/07/92       Wyborny et al.       128       419.P         52       5,137,022       08/11/92       Henry       128       419.PT         53       5,163,380       11/17/92       Duffy et al.       119       015         54       5,186,172       02/16/93       Fiddian-Green       128       632		46	5,012,411	04/30/91	Policastro et	al.	364	413.06	
49       5,117,824       06/02/92       Keimel et al.       128       419 PG         50       5,126,937       06/30/92       Yamaguchi et al.       364       413.11         51       5,127,404       07/07/92       Wyborny et al.       128       419.P         52       5,137,022       08/11/92       Henry       128       419.PT         53       5,163,380       11/17/92       Duffy et al.       119       015         54       5,186,172       02/16/93       Fiddian-Green       128       632		47	5,098,547	03/24/92	Bryan et al.		204	401	
50       5,126,937       06/30/92       Yamaguchi et al.       364       413.11         51       5,127,404       07/07/92       Wyborny et al.       128       419.P         52       5,137,022       08/11/92       Henry       128       419.PT         53       5,163,380       11/17/92       Duffy et al.       119       015         54       5,186,172       02/16/93       Fiddian-Green       128       632		48	5,109,850	05/05/92	Blanco et al.		128	635	
51     5,127,404     07/07/92     Wyborny et al.     128     419.P       52     5,137,022     08/11/92     Henry     128     419.PT       53     5,163,380     11/17/92     Duffy et al.     119     015       54     5,186,172     02/16/93     Fiddian-Green     128     632		49	5,117,824	06/02/92	Keimel et al.		128	419 PG	
52     5,137,022     08/11/92     Henry     128     419.PT       53     5,163,380     11/17/92     Duffy et al.     119     015       54     5,186,172     02/16/93     Fiddian-Green     128     632		50	5,126,937	06/30/92	Yamaguchi e	et al.	364	413.11	
53 5,163,380 11/17/92 Duffy et al. 119 015  54 5,186,172 02/16/93 Fiddian-Green 128 632		51	5,127,404	07/07/92	Wyborny et a	al.	128	419.P	
54 5,186,172 02/16/93 Fiddian-Green 128 632		52	5,137,022	08/11/92	Henry		128	419.PT	
V 34 3,180,172 02/10/93 Fiddian-Green 128 032		53	5,163,380	11/17/92	Duffy et al.		119	015	
BN 55 5,193,538 03/16/93 Ekwall 128 419 PT		54	5,186,172	02/16/93	Fiddian-Gree	en	128	632	
	BN	55	5,193,538	03/16/93	Ekwail		128	419 PT	

EXAMINER \*EXAMINER

## DATE CONSIDERED

JC38 Rec'd PCT/PTC 28 MAR 2002

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office					Attorney Doc	_	9099-21P	Application No.	
	LIST OF DOCUMENTS CITED BY APPLICANT  (Use several sheets if necessary)								To Be Assigned
		(Usi	e several sheets fi	necessary)	Applicants:	Scarantino e	t al.		
							Concurrently		Group
BN		56	5,197,466	03/30/93	Marchosky et	al.	128	399	
		57	5,205,294	04/27/93	Flach et al.		128	696	
		58	5,215,887	06/01/93	Saito		435	014	
		59	5,264,843	11/23/93	Silvian		340	870	
		60	5,309,085	05/03/94	Sohn		324	71.5	
		61	5,314,450	05/24/94	Thompson		607	032	
		62	5,324,315	06/28/94	Grevious		607	060	
		63	5,330,634	07/19/94	Wong et al.		204	409	
		64	5,354,314	10/11/94	Hardy et al.		128	653	
		65	5,354,319	10/11/94	Wyborny et a	1.	607	032	
		66	5,355,880	10/18/94	Thomas et al.		128	633	
		67	5,372,133	12/13/94	Hogen et al.		128	631	
		68	5,383,909	01/24/95	Keimel		607	5	
		69	5,425,361	06/20/95	Fenzlein et al	•	128	635	
		60	5,431,171	07/11/95	Harrison et a		128	698	
		70	5,444,254	08/22/95	Thomson		250	370.07	
		71	5,466,246	11/14/95	Silvian		607	032	
		72	5,470,345	11/28/95	Hassler et al.	<u></u>	607	36	
		73	5,476,488	12/19/95	Morgan et al.		607	030	
		74	5,480,415	01/02/96	Cox et al.		607	032	
		75	5,481,262	01/02/96	Urbas et al.		340	870.17	
		76	5,497,772	03/12/96	Schulman et	al.	128	635	
		77	5,505,828	04/09/96	Wong et al.		205	777.5	
		78	5,507,786	04/16/96	Morgan et al.		607	27	
		79	5,517,313	05/14/96	Colvin, Jr.		356	417	
		80	5,535,752	07/16/96	Halperin et a	l <b>.</b>	128	670	
		81	5,538,005	07/23/96	Harrison et a		128	698	
	/	82	5,545,187	08/13/96	Bergstrom et	al.	607	31	
BN	·	83	5,549,113	08/27/96	Halleck et al.		128	633	

JC13 Rect PST/PTC 2 6 Man 2018

FORM		U.S. Department ent and Trademark			Attorney Doc	ket Number	9099-21P	Application No.
	LIST OF DOCUMENTS CITED BY APPLICANT  (Use several sheets if necessary)							To Be Assigned
	(,	ose several sileets i	i necessary)		Applicants:	Scarantino e	t al.	-
						Concurrently		Group
BN	84	5,549,654	08/27/96	Powell		607	25	
	85	5,556,421	09/17/96	Prutchi et al.		607	36	
	86	5,562,713	10/08/96	Silvian		607	032	
	87	5,571,148	11/05/96	Loeb et al.		607	40-43	
	88	5,591,217	01/07/97	Ваптегаз		607	5	
	89	5,593,430	01/14/97	Renger		607	9	
	90	5,620,472	04/15/97	Rahbari		128	903	
	91	5,620,475	04/15/97	Magnusson		607	30	
	92	5,620,479	04/15/97	Diederich		607	97	
	93	5,626,630	05/06/97	Markowitz et	al.	607	060	
	94	5,626,862	05/06/97	Brem et al.		424	426	
	. 95	5,628,324	05/13/97	Sarbach		128	670	
	96	5,630,413	05/20/97	Thomas et al.		128	· 633	
	97	5,720,771	02/24/98	Snell		607	60	
	98	5,732,704	03/31/98	Thurston et a	1.	128	659	
	99	5,744,804	04/28/98	Meijer et al.		250	:369	
	100	5,744,805	04/28/98	Raylman et a	1.	250	370.01	
	101	5,759,199	06/02/98	Snell et al.		607	60	
	102	5,791,344	08/11/98	Schulman et	al.	128	635	
	102	5,814,089	09/29/98	Stokes et al.		607	32	
	104	5,833,603	11/10/98	Kovacs et al.		600	317	
	105		03/09/99	Larson et al.		607	30	
	100		04/06/99	Er et al.		607	27	
	, 107		06/29/99	Abraham-Fu	chs et al.	438	48	
	108	1	08/03/99	Raylman et a	1.	250	370.06	
	109		04/04/00	Mueller et al		607	61	
	110		06/13/00	Raylman et a	1.	600	436	
	/ 111		05/29/01	Alfano et al.		600	476	
BN	112		07/07/87	Thomson		250	370	

28 MAR Sheet 5 of 8

						ರ್ಟ್ ಚಿ		·	MAN CL	102
FORM	FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office					Attorney Docket Number 9099-21P			Application No.	
	LIST OF DOCUMENTS CITED BY APPLICANT								To Assig	
		(U	se several sheets if n	ecessary)			<del> </del>		<u> </u>	
						Applicants:	Scarantino	et al.		
						Filing Date	Concurrentl	y Herewith	Gro	up
BN		113	5,117,113	05/26/92	Thomson et a	<u>f</u>	250	370.07		
BN		114	5,564,434	10/15/96	Halperin et al		128	675		
									<u> </u>	
				FOREI	GN PATENT I	DOCUMENTS			<b>4</b>	
		<u>.</u>	Document Number	Date	Co	untry	Class	Subclass	Transl Yes	
BN		115	WO98/58250 '	12/23/98	PCT				х	
		116	EP0537761 '	04/21/93	ЕРО				х	
		117	DE 3219558A1	01/12/83	German					х
		118	0 420 177 A1	03/04/91	EPO				x	
		119	EP0537761A2	04/21/93	EPO				х	
		120	EP 0245073B1	22/12/93	EPO				x	
		121	DE 4341903A1	14/06/95	German					х
	ľ	122	EP 0386218B1	10/01/96	EPO				х	
		123	WO 97/33513	18/09/97	PCT					
		124	WO 98/02209A2	22/01/98	PCT		j		x	
		125	WO 98/43701	08/10/98	PCT				x	
		126	PCT/US98/05965	12/02/98	PCT				x	
		127	WO 98/58250	12/23/98	PCT				x	
1		128	WO 00/29096	25/05/00	PCT	4			х	
В	N	129	WO 95/17809	06/07/95	PCT				х	
					<u> </u>		<u></u>	<u> </u>		····
-			OTHER DOC	UMENTS (I	ncluding Autho	r, Title, Date, Pe	ertinent Page	s, Etc.)		
BN		130	International Sea	arch Report,	PCT/US00/083	10, mailed 10/2	5/00.			
		131	International Pre	liminary Exa	mination Repo	rt, PCT/US00/0	8310, mailed	11/30/01.		•
		132	Barber et al., "C Phys. 18 (3), pp.				cal probes: P	hysical charac	cterization	," Med.
V	,	133	Berthold et al., " 99-03, pp. 1-9 (\$			of tritium in we	nter," McDer	mott Technolo	ogy Inc./R	DTPA
BN	-	134	Brochure, "Be a Medic Data Syst			BMDS and Smar	t Alec <sup>TM</sup> you	r partners in i	ntelligence	e," Bio

**EXAMINER** \*EXAMINER

## DATE CONSIDERED

JC13 Record CT/PTC 28 MAR 2002

			JUIS NEW SIPPIC 20	MAR 2002				
FORM PTO-		U.S. Department of commerce	Attorney Docket Number 9099-21P	Application No.				
LIST	OF DO	CUMENTS CITED BY APPLICANT		To Be Assigned				
	(Us	e several sheets if necessary)		<u> </u>				
		•	Applicants: Scarantino et al.					
			Filing Date Concurrently Herewith	Group				
BN	135	Brochure, "Come along for the incredible jou Data Systems, Inc. (©2000).	urney in the development of the IPTT-200	," Bio Medic				
	136	Cosofret et al., "Microfabricated sensor array measurements in the beating heart," Analytic						
	137	Dewhirst, "Concepts of oxygen transport at t Oncology, Vol. 8, 1998, pp. 143-150.	he microcirculatory level," Seminars in Re	adiation				
	138	Dimitrakopoulou et al., "Studies with positro fluorine-18-uracil in patients with liver metas 1075-1081 (July 1993).	Dimitrakopoulou et al., "Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma," J. Nuc. Med., 34 (7) 1075-1081 (July 1993).					
	139	Griffiths et al., "The OxyLite: a fibre-optic o 627-630 (1999).	xygen sensor," British J. of Radiology, Vo	ol. 72 pp.				
	140	Hamburger et al., "Primary bioassay of huma July 1977).	an tumor stem cells," Science, Vol. 197, p	p. 461-463 (29				
	141	Hines, "Advanced Biotelemetry Systems for March 26-31, pp 131-137 (1995).	Hines, "Advanced Biotelemetry Systems for Space Life Sciences: PH Telemetry," Biotelementry XIII March 26-31, pp 131-137 (1995).					
	142	Hoffman et al., "Intraoperative probes and in 935 (August 1999).	Hoffman et al., "Intraoperative probes and imaging probes," Eur. J. Nuc. Med., Vol. 26, No. 8 pp. 91 935 (August 1999).					
	143	Kastrissios et al., "Screening for sources of i drug therapy: utility of population analysis,"						
	144	Kern, David, "Tumor chemosensitivity and cpp. 1447-1450 (April 1, 1997).	chemoresistance assays," Am. Cancer Soc.	, Vol. 79, No. 7,				
	145	Kissel et al., "Noninvasive determination of dynamic PET scans using the population app	the arterial input function of an anticancer proach," Med. Phys. 26 (4), pp. 609-615 (4)	drug from April 1999)				
	146	Koutcher et al., "Potentiation of a three drug pp. 3518-3523 (August 1, 1993).	chemotherapy regimem by radiation," Ca	ncer Research 53,				
	147	Ludwig Institute for Cancer Research, Annual Report 1995, http://www.icp.ucl.ac.be/report95/licr95.html.						
	148	Mackay, "Bio-Medical Telemetry, Sensing and Transmitting Biological Information from Anim Man" Second edition. New York, NY: IEEE Press (1993).						
	149	Marzouk et al., "Electrodeposited Iridium O Myocardial Acidosis during Acute Ischemia	xide pH Electrode for Measurement of Ex," Anal. Chem., Vol. 70, pp. 5054-5061 (	tracellular 1998).				
	150	Mittal et al., "Evaluation of an Ingestible Te Applications,: Int. J. Radiation Oncology Bi		perthermia				
	151	Oshima et al, "Development of Micro-Telen LSI for the clinical applications," Transduce Sensors and Actuators; pp 163-166 (1987).	netering Multi-Sensor Capsule System witers '87, The 4th International Conference of	h newly developed n Solid-State				
BN	152	Piwnica-Worms et al., "Functional imaging organotechnetium complex," Cancer Research	of multidrug-resistant P-glycoprotein with ch 53, pp. 977-984 (March 1, 1993).	an				

JC13 Resident 2 of 8 MAR 2002

			JU13 RV POINTIC 28 MA				
	Pater	U.S. Department of Commerce and Arademark Office CUMENTS CITED BY APPLICANT	Attorney Docket Number 9099-2IP	Application No. To Be Assigned			
	(Us	se several sheets if necessary)					
			Applicants: Scarantino et al.				
			Filing Date Concurrently Herewith	Group			
BN	153	Presant et al., "Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interfer or by high-dose methotrexate: an <i>in vivo</i> human study using noninvasive <sup>19</sup> F-magnetic resonance spectroscopy," J. Clinical Oncology, 18 (2) pp. 255-261 (January 2000).					
	154	Presant et al., "Human tumor fluorouracil trapping: clinical corrections of <i>in vivo</i> <sup>19</sup> F nuclear magnetic resonance spectroscopy pharmacokinetics," J. Clinical Oncology, 8 (11) pp. 1868-1873 (November 1990).					
	155	Small Business Innovation Research Program Multi-channel System for Monitoring Tumor Health Service.					
	156	Small Business Innovation Research Program Multi-channel System for Monitoring Tumor the National Institute of Health.	n Phase One Grant Application entitled "Ars," resubmitted with revisions on or about	n Implantable August 1997 to			
	157		am Phase One Grant Application entitled "An Implantable ors," resubmitted to the U.S. funding authority on or about				
	158	nonitored in vivo by <sup>19</sup> F NMR," Br. J. Canc	F NMR," Br. J. Cancer 50, pp. 113-				
	159	Taylor et al., "The Forces in the Distal Femu Measured by Telemetry," J. of Anthroplasty	otherapy for a patient by an <i>in vivo</i> assay versus a clinician," January 17, 1990).  Continuous Recording of Salivary pH Using Telemetry in an				
	160	Von Hoff et al., "Selection of cancer chemot J. Nat'l. Cancer Inst. 82 (2), pp. 110-116 (Ja					
	161	Edentulous Patient," Int'l J. Proshodontics, '					
	162	Webster, Editor, "Design of Cardiac Pacema					
	163	Wolf et al., "Potential of microsensor-based Biosensors & Bioelectronics, Vol. 12, pp. 30	01-309 (1997).				
	164	Wolf et al., "Tumor trapping of 5-fluorourac tumor-bearing humans and rabbits," Proc. N	il: <i>in vivo <sup>19</sup>F NMR spectroscopic pharmac</i> atl. Acad. Sci. USA, 87, pp. 492-496 (Janu	cokinetics in lary 1990).			
	165	Yarnell et al., "Drug assays on organ culture 490-491 (1964).	s of biopsies from human tumours," Brit. N	Леd., J., 2, pp.			
	166	Zanzonico et al., "The intraoperative gamma Nucl. Med., XXX (1), pp. 33-48 (January 20		ble," Seminars in			
	167	Zuckier et al., "Remotely Pollable Geiger-M Therapy Patients," J. of Nuclear Med., Vol.	39, No. 9, pp. 1558-1562 (9/98).	· · · · · · · · · · · · · · · · · · ·			
	168	Fernald, "A microprocessor-based system for biomedical research applications", Doctoral (1992).	or the fast prototyping of implantable instru Dissertation, Elect. & Computer Eng., NC	ments for State Univ.,			
ВN	169	Gerweck, "Tumor pH: Implications for Trea Oncology, No. 5, pp. 176-182 (July 1998).	atment and Novel Drug Design," 8 Seminar	s in Radiation			

**EXAMINER** 

28 MAR 2002

	Pater OF DO	U.S. Department of Commerce nt and Trademark Office  CUMENTS CITED BY APPLICANT e several sheets if necessary)	Attorney Docket Number 9099-21P	Application No. To Be Assigned			
	·	•	Applicants: Scarantino et al.				
			Filing Date Concurrently Herewith	Group			
BN	170	Gilligan et al., "Evaluation of a subcutaneou Care, Vol. 17, pp. 882-887 (1994).	Gilligan et al., "Evaluation of a subcutaneous glucose sensor out to 3 months in a dog model," <i>Diabetes Care</i> , Vol. 17, pp. 882-887 (1994).				
	171	Gschwend et al., "A general-purpose implan research," Biotelemetry Patient Monitoring,		siological			
	Mueller et al., "Feasibility of inductive powering of miniature low-power biotelemetry for use with microfabricated biomedical sensors," Proc. Biotelemetry XIII, Williamsburg, VA, pp. 372-377 (Mar. 1995).						
BN	Williams et al. "Multinum es ahin for physiological maggyraments." IEEE International Summerium on						